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ABSTRACT
Purpose: To observe hypogonadal men undergoing testosterone replacement therapy (TRT) and assess racial differences 
in hypogonadal improvement and prostate-specific antigen (PSA) levels.
Materials and Methods: In a retrospective analysis, 75 hypogonadal men were followed for an average 34 months after 
initiating TRT. Total testosterone and PSA levels were assessed every 6 months, and patients diagnosed with prostatitis or 
prostate cancer during treatment were excluded.
Results: For 16 African American men, the average age at diagnosis of hypogonadism was 53.5 years, compared with 
57.8 years in 59 Caucasian men (p = NS). Pre- and post-treatment testosterone was 219 ng/dL and 310 ng/dL in African 
American men, and 247 ng/dL and 497 ng/dL in Caucasian men (p = NS). Symptomatic response was 81% in African 
American men and 93% in Caucasian men (p = NS). Baseline PSA level was 1.32 ng/mL in African American men and 
1.27 ng/mL in Caucasian men, and there was no significant difference in PSA between racial groups at 6-month intervals, 
although there was a small decreasing trend in the PSA of African Americans compared with Caucasians.
Conclusions: Hypogonadal African American men have a similar normalization of testosterone and symptomatic response 
as hypogonadal Caucasian men, and PSA levels remain stable over time in both groups.  In this hypogonadal cohort, in 
contrast to studies of eugonadal men, higher PSA levels in African Americans were not observed.
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INTRODUCTION
 Testosterone deficiency syndrome (TDS) is a 
condition characterized by serum androgen deficiency 
that adversely affects the function of multiple organ 
systems and negatively impacts quality of life. The 
clinical symptoms include sexual dysfunction such 
as erectile dysfunction and decreased libido, as well 
as fatigue, depressed mood, impaired cognition, and 
decreased muscle mass (1). Although the majority 
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of cases of TDS occur in aging men, for which the 
syndrome is commonly referred to as late-onset hy-
pogonadism or andropause, TDS can also occur in 
younger men. Treatment of TDS with testosterone 
replacement therapy (TRT) is appropriate when the 
testosterone level is below the lower limit of normal, 
generally accepted to be 300 ng/dL (2).
 An extrapolation from the Massachusetts 
Male Aging Study found a prevalence of TDS of 
almost half a million new cases per year in men in 
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their fifth, sixth and seventh decades of life, and as a 
result of the expanding population of the elderly, the 
incidence of TDS is on the rise (3). Racial differences 
of the prevalence and incidence of TDS are unknown 
because epidemiologic series on the subject have been 
primarily comprised of Caucasian men.
 The beneficial effects of TRT in the treatment 
of TDS are well characterized. As levels of serum tes-
tosterone are normalized, the desired improvements 
in sexual function, mood, cognition, and muscle mass 
can be achieved. The question of how TRT affects 
racial groups differently has not been addressed in 
previous studies. It is unknown if different racial 
groups normalize testosterone levels with the same 
vigor, or if the same symptomatic response can be 
achieved.
 Racial differences of androgen levels of 
eugonadal men have been previously examined, 
although the results of many studies are discordant. 
While several previous studies have shown African 
American men to have higher baseline testosterone 
levels than Caucasian men (4-7), others have shown 
no differences (8-12). One of the largest prospective 
studies of racial differences of serum androgen levels 
in eugonadal men found no significant differences 
in total testosterone, bioavailable testosterone, or 
sex-hormone binding globulin levels in 538 African 
American, 651 Hispanic, and 710 Caucasian men 
(13).
 The average prostate-specific antigen (PSA) 
level of African American men has been shown in 
multiple studies to be higher than the average PSA 
level of Caucasian men, both in eugonadal men with 
a new diagnosis of prostate cancer (14), as well as in 
eugonadal men without prostate cancer (15-17). Moul 
and colleagues examined the PSA level of 541 men 
with newly diagnosed prostate cancer and reported 
that after adjusting for stage, grade, and age, the mean 
PSA value for 133 African American men was 14.00 
ng/mL compared with 8.29 ng/mL for 408 Caucasian 
men (p < 0.001) (14). To study racial differences in 
PSA level and PSA density in men without prostate 
cancer, a retrospective study of 826 consecutive men 
who underwent prostate biopsy was performed. Of 
the 498 men with negative biopsies, serum PSA lev-
els (7.97 ng/mL versus 4.30 ng/mL, p < 0.0001) and 
calculated PSA density (0.19 versus 0.11, p < 0.0001) 
were significantly higher in African American men 
than in Caucasian men (15).
 This difference in PSA has been shown to not 
be the result of racial differences in prostate size.  In 
a study of 11,011 men who underwent prostatectomy, 
race and serum PSA values were correlated to prostate 
weight, and although serum PSA was 15% higher 
in African American men there were no significant 
associations between race and prostate size (17). 
As described above, racial differences of androgen 
levels have not been definitely proven to be higher 
in African Americans even though this potential dif-
ference may partially explain the difference in PSA 
levels given the strong positive association between 
prostate size and serum PSA value (18). Racial dif-
ferences in hormones such as estrogen, insulin, and 
insulin-like-growth factor that also regulate prostate 
size may augment or even negate the potential an-
drogenic difference. Other theories that have been 
investigated to explain the racial difference in PSA 
include genetic polymorphisms. African Americans 
are more likely to possess polymorphisms favoring 
increased androgen activity, including shorter CAG 
trinucleotide repeats in the androgen receptor gene 
and a less active CYP3A4 gene which is involved 
with the deactivation of testosterone (19,20).
 Both short-term and long-term changes in 
the PSA levels of hypogonadal men undergoing TRT 
have been reported. A review of 18 short-term TRT 
trials found an average initial increase in PSA level of 
0.3 ng/mL, and the same authors reported that in six 
studies of short-term TRT in slightly older men with 
TDS, there was a higher average increase in PSA level 
of 0.43 ng/mL (21). Rhoden and Morgentaler reported 
that 579 hypogonadal men on TRT from nine differ-
ent studies, with a duration of treatment of about one 
year, had a mean PSA level increase of 0.46 ng/mL 
(22). Wang et al. reported that in 163 hypogonadal 
men on TRT for 3 years, after a small initial increase 
in PSA level of 0.26 ng/mL at 6 months, there were 
no further PSA level increases with continued TRT 
over the following 3 years (23). In another study of 
187 hypogonadal men on TRT, there were no signifi-
cant differences in PSA after one year (24). With the 
longest follow-up data available, a recent study of 
81 hypogonadal men on TRT found that PSA levels 
remain stable after normalization of testosterone for at 
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least 5 years (25). The racial differences in PSA levels 
of hypogonadal men undergoing TRT are unknown.
 The aim of the present study was to retro-
spectively review patients undergoing TRT for TDS 
to evaluate the racial differences in hypogonadal 
improvement and PSA levels. We hypothesized that 
the normalization of testosterone levels, as well as 
the symptomatic responses, will be similar among 
hypogonadal Caucasian and African American men 
undergoing TRT. Based on previous studies of race 
and PSA, we also hypothesized that the PSA levels of 
African American men with TDS will be higher than 
the PSA levels of Caucasian men.
MATERIALS AND METHODS
 The medical records of all men evaluated in 
the Urology Clinic at our institution from January 
2000 through June 2006 were queried for a diag-
nosis of hypogonadism by International Center for 
Diseases-9 (ICD-9) code 257.2, yielding 267 men 
initially. In order to be diagnosed with hypogonadism, 
the patient must have reported symptoms in addition 
to having had a serum testosterone level below 300 
ng/dL. Men then must have been seen in our clinic at 
least two or more times with the diagnosis.
 For inclusion in the study, full demographic 
information must have been available, and each pa-
tient must have had an initial testosterone and PSA 
level. The patients must have been started on TRT 
and then had at least one subsequent testosterone 
level and PSA level measured within one year of 
initiating TRT. All men included in the study had a 
normal baseline PSA level prior to initiating TRT and 
underwent routine digital rectal examinations during 
treatment. Patients with a biopsy-proven diagnosis or 
recent history of prostatitis prior to treatment were ex-
cluded from the study. Four men were diagnosed with 
prostate cancer while on TRT and were excluded. The 
decision to perform prostate biopsy during TRT was 
made at the discretion of the clinician (CCC) without 
strict criteria, but all four men with diagnosed cancer 
had an abnormally increased PSA velocity with two 
consecutive PSA elevations. Further details of the men 
diagnosed with prostate cancer have been previously 
published (25). One Asian male, and one male with 
race listed as “other,” were excluded secondary to 
insufficient numbers. After applying these criteria, 
75 men with TDS were selected for a complete chart 
review.
 Each patient’s age at the time of diagnosis, 
and race, were identified as demographic data. The 
patient’s symptomatic response to treatment was 
determined subjectively by the patient in follow-
up clinic visits as either a positive response or no 
response. Comorbid conditions including benign 
prostatic hyperplasia (BPH), coronary artery disease, 
diabetes mellitus type 2, hypertension, hyperlipid-
emia, and obstructive sleep apnea were also assessed. 
BPH was specifically assessed by the clinician prior 
to initiating TRT by querying for lower urinary tract 
symptoms and by digital rectal examination. The 
other comorbid conditions were identified through 
chart review rather than ICD-9 coding, and were not 
defined by strict criteria.
 Testosterone and PSA levels were drawn 
during a morning clinic, generally between 9 a.m. 
and 12 p.m., although the exact time varied and was 
not recorded. The PSA level was performed by UNC 
McLendon Laboratories (Chapel Hill, NC), and the 
total and free testosterone levels were performed by 
Mayo Medical Laboratories (Rochester, MN). The 
free testosterone was calculated with a direct radioim-
munoassay. The form of TRT was selected by patient 
preference, and both the form and dose were not con-
sistently available. The target testosterone level was 
a eugonadal level (> 300 ng/dL) with symptomatic 
improvement, and the dose was titrated accordingly 
by the clinician.
 The patients were evaluated in regular six-
month intervals, and rarely if the treatment dates 
were not exactly at 6 months they were rounded to the 
closest six-month interval. Basic statistical data was 
obtained at each 6-month interval for all variables. 
The data were compared using a Student’s-t-test, with 
p < 0.05 considered statistically significant.
RESULTS
 Patient characteristics are available in Table-
1. For 16 African American men, the average age at 
diagnosis of TDS was 53.5 years (range 41-56), com-
703
Race and PSA in Hypogonadism
pared with 57.8 years (range 25-82) in 59 Caucasian 
men (p = NS). The mean follow-up for Caucasian 
men was 36.9 months compared with 23.3 months for 
African American men (p = NS). Among comorbid 
conditions, Caucasian men had more BPH (44.1% 
versus 12.5%, p < 0.05), and African American men 
had a higher prevalence of diabetes mellitus type 2 
(56.3% versus 22%, p < 0.05).
 Pre- and post-treatment (after 1 year) total 
testosterone levels were 247 ng/dL and 497 ng/dL in 
Caucasian men (p < 0.05), and 219 ng/dL and 310 
ng/dL in African American men (p < 0.05). When the 
pre-treatment total testosterone level of 247 ng/dL for 
the Caucasian cohort was compared with the pre-treat-
ment level of 219 ng/dL in African Americans, there 
was no significant difference (p = NS). Similarly, 
the post-treatment total testosterone levels were not 
statistically different when the two racial cohorts 
were compared, 497 ng/dL in Caucasian men versus 
310 ng/dL in African American men (p = NS). Total 
testosterone levels remained eugonadal at 3 years 
after initiating TRT, with 355.3 ng/dL in Caucasian 
men and 326.3 ng/dL in African American men. 
Free testosterone levels were 7.68 ng/dL and 9.14 
Table 1 – Patient characteristics.
Caucasian Men African American Men
Number of patients                      59                          16
Age (years) 57.8 53.5
Follow-up (months) 36.9 23.3
BMI (kg/m2) 31.3 32.7
Comorbidities (%)
BPH 44.1   12.5*
Hypertension 47.4 56.3
Coronary artery disease 23.7 25.0
Diabetes mellitus 22.0   56.3*
Hyperlipidemia 33.9 56.3
Obstructive sleep apnea 10.2 0
Baseline PSA (ng/mL)     1.27      1.32
*p < 0.05  BMI = body mass index; BPH = benign prostatic hyperplasia;  PSA =prostate-specific antigen.
Table 2 – Racial differences in biochemical and symptomatic responses to TRT.
Caucasian Men African American Men
Total testosterone (ng/dL)
Baseline 246.6 218.9
1 year 496.6 310.1
3 years 355.3 326.3
Free testosterone (ng/dL)
Baseline       7.68       9.14
1 year     15.63       9.97
3 years     13.23       8.95
Symptomatic Response (%)   93.2   81.3
*p = NS;  TRT = testosterone replacement therapy.
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ng/dL in Caucasian men and African American men, 
respectively. At one year, free testosterone after TRT 
increased to 15.63 ng/dL in Caucasians and 9.97 ng/dL 
in African Americans, and these values were consis-
tent at 3 years, with 13.23 ng/dL for Caucasians and 
8.95 ng/dL in African Americans. The symptomatic 
response was 81% in African American men and 93% 
in Caucasian men, although this was not statistically 
different. The racial differences in the biochemical 
and symptomatic response are listed in Table-2.
 The baseline PSA level was 1.32 ng/mL in 
African American men and 1.27 ng/mL in Caucasian 
men. The changes in PSA levels in 6-month intervals 
are listed in Table-3 and are displayed in Figure-1. 
At 6-month intervals, there was a small decreasing 
trend in the PSA level of African American men over 
2 years of treatment compared with Caucasian men. 
However, none of the differences in PSA levels be-
tween the two racial cohorts at each time point were 
statistically significant, and the PSA levels remained 
stable over the 2 year period in all men.
COMMENTS
 In hypogonadal men treated with TRT, ra-
cial differences in hypogonadal improvement have 
not been previously reported. In the present study, 
symptomatic hypogonadal African American men had 
comparable baseline testosterone levels as Caucasian 
men. Additionally, the symptomatic and biochemical 
responses of total testosterone achieved at 1 year and 
at 3 years were similar between the two cohorts. The 
free testosterone levels of African American men did 
not respond to TRT with the same vigor as the total 
testosterone. Sex hormone binding globulin levels 
were unavailable in this study, and therefore the dis-
crepancy between total and free testosterone cannot 
be further explained. These data suggest that there 
are no racial differences in hypogonadal improve-
ment among hypogonadal Caucasian and African 
American men undergoing TRT. This is consistent 
with eugonadal men, as studies vary as to whether a 
racial difference in androgen levels exists (4-12).
Table 3 – Racial differences in PSA level.
*p = NS; PSA = prostate-specific antigen; SD = standard deviation.
Caucasian Men
PSA Level (ng/mL) ± SD
African American Men 
PSA Level (ng/mL) ± SD
Baseline 1.27 ± 1.04 1.32 ± 0.78
6 months 1.39 ± 0.98 1.24 ± 0.64
12 months 1.61 ± 1.47 1.19 ± 0.64
18 months 1.44 ± 1.43 1.00 ± 0.53
24 months 1.38 ± 1.04 1.28 ± 0.49
Figure 1 – Comparing prostate-specific antigen (PSA) change of African American men (AAM) versus Caucasian men (CM) treated 
with testosterone replacement therapy in 6-month intervals. 
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 Population-based studies have shown that 
African American men have higher PSA levels than 
Caucasian men (14-17). The racial differences in 
PSA levels of hypogonadal men, and how the PSA 
changes during TRT among different races, have not 
been published before this study. Several previous 
studies have reported that PSA either remains stable, 
or has a small initial increase that stabilizes over 
time (21-25). In the small cohort of hypogonadal 
men in the present study, the baseline PSA was not 
different between the racial groups, with 1.32 ng/mL 
in African American men and 1.27 ng/mL in Cauca-
sian men (p = NS). After initiation of TRT, the PSA 
was followed every 6 months for a two year period, 
and there was a small decreasing trend without 
statistical significance in the PSA levels of African 
American men over 2 years of treatment compared 
with Caucasian men, although the PSA remained 
stable over time in all men. The higher mean PSA 
level of eugonadal African American men that has 
been previously reported was not observed in our 
cohort of hypogonadal men. Furthermore, after two 
years of TRT resulting in a corrected, eugonadal 
total testosterone level, the PSA did not increase in 
6-month intervals. These data suggest that androgens 
are less likely to play a role in the higher baseline 
PSA levels of eugonadal African American men; 
however, further research is necessary to explain 
the observed racial differences in the PSA levels of 
eugonadal men.
 This study has several important limita-
tions. All of the standard limitations inherent to 
a retrospective chart review apply to this study. 
The sample size was small with 75 men, and the 
two racial groups were not well matched, with 
only 16 African American men compared with 59 
Caucasian men. It can be argued that with only 
16 African American men that the study is under-
powered to identify a true racial difference if there 
indeed is one. This discrepancy can lead to selec-
tion bias that can adversely affect the results. The 
follow-up period for the Caucasian men was longer 
with a mean 36.9 months versus 23.3 months for 
the African Americans. The reason for the differ-
ent follow-up period is simply that the African 
American men were lost to follow-up earlier, and 
this is a limitation of a retrospective study. It is 
unclear whether the discrepancy in follow-up time 
affects the results, although ideally the follow-up 
period would be equal between the two cohorts. The 
doses of testosterone and delivery system were not 
consistently available and therefore were not report-
able, and these data would be useful correlative data 
to the biochemical and symptomatic response data. 
The assessment of a symptomatic response was only 
quantified in this study by either a positive response 
or no response, and ideally a validated questionnaire 
to assess the response would be preferred, although to 
our knowledge one does not exist. The prevalence 
of BPH was higher in the Caucasian group, 44.1% 
versus 12.5% (p < 0.05), and because of the positive 
association between prostate size and serum PSA 
value, these differences in BPH could affect the base-
line PSA level (18). Additionally, diabetes mellitus 
occurs in a higher incidence in the African American 
group at 56.3% versus 22.0% in the Caucasian group 
(p < 0.05). Because hypogonadism is a component 
of metabolic syndrome and can be associated with 
insulin resistance and diabetes mellitus, the racial 
difference in the prevalence of diabetes mellitus may 
confound the analysis (26). There are too few subjects 
to adjust for the difference in diabetes mellitus, but it 
can explain the difference of the baseline testosterone 
level and ultimately the PSA.
CONCLUSIONS
 With these limitations in mind, and under-
standing that this is a small, retrospective study, we 
can make several useful conclusions based on the fact 
that this is the first study to report the racial differ-
ences in hypogonadal improvement and PSA changes 
in men undergoing TRT. Hypogonadal African 
American men had a similar normalization of total 
testosterone and symptomatic response as Caucasian 
men undergoing TRT. PSA levels over time trended 
slightly lower in hypogonadal African American men 
on TRT compared with Caucasian men, although the 
PSA remained stable in all men. In this hypogonadal 
cohort, in contrast to other studies of eugonadal men, 
higher PSA levels in African Americans were not 
observed. Larger, prospective studies are necessary 
to confirm these findings.
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This is a very high rate of clinical response and may 
reflect strict inclusion criteria, specially related to the 
levels of baseline testosterone (218 and 246 ng/dL). 
An important limitation of the current study is the fact 
that the authors considered only subjective evaluation 
to characterize clinical response. This aspect limits 
major considerations regarding clinical response 
evaluation. Certainly, the major improvements were 
related to patient sexual concerns. However, appropri-
ate objective evaluation is recommended and there are 
several tools available in the literature for this purpose. 
A high rate of clinical response (overall 70%) to TRT 
could also be observed in a recent study, Rhoden and 
Morgentaler (1). Even with a shorter follow-up in this 
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study the first 3 months response was a pivotal issue 
in maintaining men on TRT.
 Another aspect analyzed in the current study 
was the influence of TRT on PSA levels regarding 
race. It is well recognized that African America men 
are of greater risk for developing prostate cancer and 
that PSA is the most important marker for early diag-
nosis. There was no significant increase in PSA levels 
before and after initiating TRT independently of the 
race group. In a review of the literature of 579 hypo-
gonadal men under TRT the mean increase in PSA 
levels was 0.46 ng/mL (2). Some authors observed 
in their series that after a small initial increase (mean 
0.26 ng/mL), no further increases in general was 
observed (3). Also other authors (2) demonstrated, 
that in a selected population free of prostate cancer, 
based in a prior biopsy before starting TRT, that PSA 
decreased in 21%, unchanged in 22%, and increased 
in 57% cases. All of this information supports the fact 
of the limited influence of testosterone levels and PSA 
levels (4). One of the possible explanations regarding 
this issue is the fact that exogenous testosterone does 
not raise intraprostatic concentrations of testosterone 
or dihydrotestosterone, suggesting a saturation model. 
Based on this concept androgens exert their prostatic 
effects primarily via binding to the androgen receptor 
(AR), and maximal androgen-AR binding is achieved 
at serum testosterone concentrations well below 
the physiologic range. Finally, prostate function is 
exquisitely sensitive to variations in androgen con-
centrations at very low concentrations, but becomes 
insensitive to changes in androgen concentrations at 
higher levels (5). Based on this concept the current 
study demonstrates that testosterone levels have a lim-
ited effect on changes in PSA levels independently of 
race when hypogonadal (non-castrated) are submitted 
to TRT restoring testosterone levels to an eugonadal 
status.
REFERENCES
1. Rhoden EL, Morgentaler A: Symptomatic response 
rates to testosterone therapy and the likelihood of 
completing 12 months of therapy in clinical practice. 
J Sex Med. 2010; 7: 277-83.
2. Rhoden EL, Morgentaler A: Influence of demographic 
factors and biochemical characteristics on the pros-
tate-specific antigen (PSA) response to testosterone 
replacement therapy. Int J Impot Res. 2006; 18: 201-
5.
3. Wang C, Cunningham G, Dobs A, Iranmanesh A, Mat-
sumoto AM, Snyder PJ, et al.: Long-term testosterone 
gel (AndroGel) treatment maintains beneficial effects 
on sexual function and mood, lean and fat mass, and 
bone mineral density in hypogonadal men. J Clin 
Endocrinol Metab. 2004; 89: 2085-98.
4. Morgentaler A, Schulman C: Testosterone and prostate 
safety. Front Horm Res. 2009; 37: 197-203.
5. Morgentaler A, Traish AM: Shifting the paradigm of 
testosterone and prostate cancer: the saturation model 
and the limits of androgen-dependent growth. Eur 
Urol. 2009; 55: 310-20.
Dr. Ernani L. Rhoden
Section of Urology
Porto Alegre Federal University of Health Sciences
Rio Grande do Sul, Brazil
E-mail: ernanirhoden@yahoo.com.br
EDITORIAL COMMENT
 The diminution in serum androgen levels in 
aged men has been extensively studied. The mecha-
nisms of this phenomenon have not been fully illus-
trated, and are probably multifactorial, involving the 
hypothalamic-pituitary-testicular axis. The greatest 
concerns regarding testosterone replacement therapy 
is the fear of causing or promoting prostate cancer. A 
decline in testicular function with a consequent de-
cline in testosterone level is recognized as a common 
occurrence in older men (1). Androgens regulate the 
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function and growth of the prostate and may contrib-
ute to the development of prostate cancer and benign 
prostatic hypertrophy (2).
 The effect of parenteral testosterone replace-
ment therapy on prostatic specific antigen (PSA) level 
or the development or growth of prostate cancer is 
unclear. This has prompted many investigators to 
investigate the effect of this treatment on serum PSA 
levels in hypogonadal men with erectile dysfunction. 
Previous studies have shown no significant differ-
ences between the baseline levels of mean, median, 
and range of PSA and categories of PSA level (nor-
mal, borderline, high) at one year post-testosterone 
therapy (3). In the present study, the authors elegantly 
demonstrated that Hypogonadal African American 
men have a similar normalization of testosterone 
and symptomatic response as hypogonadal Cauca-
sian men, and PSA levels remained stable over time 
in both groups. However, more long-term studies 
are warranted to further investigate the relationship 
between testosterone replacement and PSA level and 
to better clarify the effects of parenteral testosterone 
replacement therapy on the development or growth 
of prostate cancer.
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